Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymectomy for Myasthenia Gravis.

Gary S. Gronseth1, Richard J. Barohn

  • 1*Department of Neurology, Willford Hall United States Air Force Medical Center, 2200 Bergquist Drive, Suite 1, Lackland, TX 78236, USA. gary.gronseth@59mdw.whmc.af.mil

Current Treatment Options in Neurology
|April 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Painful Peripheral Neuropathy.

Current treatment options in neurology·2002
Same author

Peripheral Neuropathy Due to Leprosy.

Current treatment options in neurology·2002
Same author

Peripheral Neuropathy Due to Cobalamin Deficiency.

Current treatment options in neurology·2002
Same author

Diabetic Lumbosacral Polyradiculoneuropathies.

Current treatment options in neurology·2001

Thymectomy may improve outcomes for myasthenia gravis (MG) patients, but evidence is limited. Studies show benefits, but patient differences between surgical and non-surgical groups confound results, leaving thymectomy

Area of Science:

  • Neurology
  • Immunology
  • Surgical Research

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
  • Thymectomy is a surgical procedure involving the removal of the thymus gland, often considered for MG treatment.
  • Existing evidence on thymectomy's effectiveness in non-thymomatous autoimmune MG is primarily from lower-class studies.

Purpose of the Study:

  • To evaluate the effectiveness of thymectomy in improving outcomes for myasthenia gravis patients.
  • To determine if observed improvements in MG patients undergoing thymectomy are attributable to the procedure itself or confounding patient characteristics.

Main Methods:

  • Review and analysis of Class II studies comparing MG patients who underwent thymectomy versus those who did not.

Related Experiment Videos

  • Assessment of confounding factors, including age, sex, and disease severity, between surgical and non-surgical groups.

    • Main Results:

    • Class II studies suggest higher remission and improvement rates in MG patients who underwent thymectomy.
    • Significant baseline differences were observed between surgical and non-surgical groups, including younger age, higher female proportion, and greater disease severity in the thymectomy group.
    • These confounding factors prevent definitive conclusions about the causal benefit of thymectomy.

    Conclusions:

    • The benefit of thymectomy for non-thymomatous autoimmune myasthenia gravis has not been conclusively established.
    • Thymectomy should be considered an option to potentially increase the probability of remission or improvement in these patients.
    • This conclusion aligns with the position adopted by the American Academy of Neurology's quality standards subcommittee.